drugset / Trial / NCT00077454
Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This phase I trial is studying the side effects and best dose of erlotinib when given with temozolomide in treating young patients with recurrent or refractory solid tumors. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving erlotinib with temozolomide may kill more tumor cells.
Timeline
- Start
- 2004-02
- Primary completion
- 2007-09
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erlotinib | Small molecule | — | Oral |
| Subject | Temozolomide | Small molecule | — | Oral |